DEVELOPMENT OF EXTRA-MUSCULOSKELETAL MANIFESTATIONS IN UPADACITINIB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, OR NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
Abstract: OP0061
Authors: D. Poddubnyy et al.
Key content:
Upadacitinib is licensed in Switzerland for RA, psoriatic arthritis (PsA) and ankylosing spondylitis (AS). There is limited data on the effects of Upadacitinib on extramusculoskeletal manifestations, including uveitis, inflammatory bowel disease (IBD) and psoriasis, in patients with spondyloarthritis. This abstract reports an analysis of safety data of trials of Upadacitinib in PsA, AS and non-radiographic axSpA. Over 90% of the patients did not have extramusculoskeletal manifestations (EMM) before inclusion in the studies. In PsA studies, the occurrence of IBD and uveitis was low, irrespective of treatment (Upa or placebo). In the AS studies the occurrence of uveitis was numerically higher in the placebo group and also in patients with prior history of uveitis. IBD and psoriasis were low, irrespective of treatment or prior history. In nr-axSpA the rate of uveitis was numerically higher in placebo vs Upa treated patients, but the incidence was low irrespective of prior history. Also, IBD and psoriasis was low or absent in nr-axSpA patients irrespective of treatment or prior history.
Relevance:
This study shows, that treatment with Upadacitinib of patients with PsA, AS and nr-axSpA was not associated with an increased incidence of uveitis, IBD or psoriasis. In AS and nr-axSpA uveitis was numerically more frequent in placebo as compared to Upa treated patients. The data suggests that Upa can be used safely in patients with these diseases, also in case of a prior history of uveitis or IBD.
Whether there is a protective effect of Upa on uveitis development in these patients needs to be assessed in a clinical study.
